The cost‐effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data

References

• Ward M. M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002; 46: 223–31
   PubMed Web of Science ®Google Scholar
• Boonen A., Severens J. L. Ankylosing spondylitis: what is the cost to society, and can it be reduced?. Best Pract Res Clin Rheumatol 2002; 16: 691–705
   PubMed Web of Science ®Google Scholar
• Boonen A., van der Heijde D., Landewe R., Spoorenberg A., Schouten H., Rutten‐van Molken M., et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429–37
   PubMed Web of Science ®Google Scholar
• Kobelt G., Andlin‐Sobocki P., Brophy S., Jonsson L., Calin A., Braun J. The burden of ankylosing spondylitis and the cost‐effectiveness of treatment with infliximab. Rheumatol 2004; 43: 1158–66
   PubMed Web of Science ®Google Scholar
• Kobelt G., Andlin‐Sobocki P., Rousseau C., Maksymowych W. Cost and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006; 33: 289–95
   PubMed Web of Science ®Google Scholar
• Kobelt G., Sobocki P., Collantes‐Estevez E., Gratacos‐Masmita J., Pocovi A., Mlero‐Mendoza J. The cost of ankylosing spondylitis in Spain. An observational study in 600 patients. THU0550. Ann Rheum Dis 2006; 65(Suppl II): 282
   Google Scholar
• Kobelt G., Sobocki P., Collantes‐Estevez E., Gratacos‐Masmita J., Pocovi A., Mulero J. The burden of ankylosing spondylitis in Spain. Value in Health 2007, DOI: 10.1111/j.1524‐4733.2007.00252
   Google Scholar
• Calin A., Barrett S., Whitelock H., Kennedy L. G., O'Hea L., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5
   PubMed Web of Science ®Google Scholar
• Taylor A., Balakrishnan C., Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998; 41: 1119–25
   PubMedGoogle Scholar
• Szende A., Williams A. EuroQoL scores in Europe. 2004, Budapest, The EuroQol Group, 2004
   Google Scholar
• Braun J., Baraliakos X., Godolias G., Bohm H. Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005; 34: 97–108
   PubMed Web of Science ®Google Scholar
• Braun J., Baraliakos X., Brandt J., Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in spondylarthropathies. Scand J Rheumatol 2005; 34: 178–90
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006; 35: 415–25
   PubMed Web of Science ®Google Scholar
• Kobelt G., Andlin‐Sobocki P., Maksymowych W. The cost‐effectiveness of infliximab in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006; 33: 732–40
   PubMed Web of Science ®Google Scholar
• Kobelt G., Sobocki P., Sieper J., Braun J. A comparison of the cost‐effectiveness of infliximab in the treatment of ankylosing spondylitis in the UK based on two different clinical trials. Int J Technol Assess Health Care 2007; 23: 368–75
   PubMed Web of Science ®Google Scholar
• Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93
   PubMed Web of Science ®Google Scholar
• J B, Brandt J., Listing J., Zink A., Alten R., Burmester G., et al. Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open observational extension study of a three‐month randomized placebo‐controlled trial. Arthritis Rheum 2003; 48: 2224–33
   PubMedGoogle Scholar
• Braun J., Brandt H., Listing J., Listing J., Zink A., Burmester G., et al. Two‐year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 229–34
   PubMed Web of Science ®Google Scholar
• Braun J., Baraliakos X., Brandt J., Listing J., Zink A., Altern R., et al. Persistent clinical response to the anti‐TNF‐alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005; 44: 670–6
   PubMed Web of Science ®Google Scholar
• Myckatyn S., Mallon C., Russell A., Maksymowych W. 3 Year follow‐up of a prospective observational inception cohort of ankylosing spondylitis patients on low‐dose (3 mg/kg) infliximab. Ann Rheum Dis 2004; 63(Suppl 1): 408
   Google Scholar
• Van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo/controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–91
   PubMed Web of Science ®Google Scholar
• Collantes‐Estevez E., Munoz‐Villanueva M., Zarco P., Torre‐Alonso J. C., Gratacos J., Gonzalez C., et al. Infliximab in refractory spondylarthropathies: a multicenter 38‐week open study. Ann Rheum Dis 2003; 62: 1239–40
   PubMed Web of Science ®Google Scholar
• Collantes‐Estevez E., Munoz‐Villanueva M., Zarco P., Torre‐Alonso J. C., Gratacos J., Gonzalez C., et al. Effectiveness of reducing infliximab dose interval in non‐responder patients with refractory spondylarthropathies. An open extension of a multicentre study. Rheumatol 2005; 44: 1555–8
   PubMedGoogle Scholar
• Keat A., Barkham N., Bhalla A., Gaffney K., Marzo‐Ortega H., Paul S., et al. BSR guidelines for prescribing TNF‐alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005; 44: 939–47
   PubMedGoogle Scholar
• EuroQol Group. EuroQol – a new facility for the measurement of health‐related quality of life. Health Policy 1990; 16: 199–208
   PubMed Web of Science ®Google Scholar
• Dolan P., Gudex C., Kind P., Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York, York 1995, Discussion paper 138
   Google Scholar
• Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174–6
   PubMed Web of Science ®Google Scholar
• Jois R. N., Leeder L., Gibb A., Gaffney K., Macgregor A., Somerville M., et al. Low‐dose infliximab treatment for ankylosing spondylitis – clinically‐ and cost‐effective. Rheumatology (Oxford) 2006; 45: 1566–9
   PubMed Web of Science ®Google Scholar
• Kristensen L. E., Saxne T., Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five‐year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600–6
   PubMed Web of Science ®Google Scholar
• Carmona L., Gomez‐Reino J. J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72
   PubMed Web of Science ®Google Scholar
• Baraliakos X., Listing J., Rudwaleit M., Brandt J., Sieper J., Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005; 64: 1462–6
   PubMed Web of Science ®Google Scholar
• Boonen A., van der Heijde D., Severens J. L., Boendemaker A., Landdewe R., Braun J., et al. Markov model into the cost‐utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006; 65: 201–8
   PubMedGoogle Scholar
• Koopmanschap M. A., Rutten F. F., van Ineveld B. M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89
   PubMed Web of Science ®Google Scholar